Posts Tagged: "patent"

On January 7, the United States Court of Appeals for the Federal Circuit (CAFC) dismissed ABS Global’s appeal from the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB) as moot. Cytonome/st, LLC had disavowed its ability to challenge a district court’s summary judgment that ABS did not infringe claims of the patent in suit and ABS did not establish that it engaged in or had “sufficiently concrete plans to engage in activities not covered by” Cytonome’s disavowal (ABS Global, Inc. v. Cytonome/st, LLC), said the court. The majority denied ABS’s request for vacatur and Chief Judge Prost wrote separately to dissent on the issue of vacatur.

Combining the holiday break, we see a steady 24 and 25 Patent Trial and Appeal Board (PTAB) petitions filed in the last two weeks, respectively, with 84 and 71 District Court complaints filed, respectively. The 84 was again bumped up roughly 10 by another round of WSOU filings, this time against Salesforce; otherwise it was the typical mix of small file-and-settle non-practicing entity (NPE) additions (mostly IP Edge, seemingly filling out some kind of annual quotas, and with a new campaign against shuttle services), bigger funded NPEs like Acacia and Dominion Harbor entities, small filers, and a smattering of company-company filings. Cedar Lane also ended the year strong, adding a few logs to the yule fire.

On January 5, the United States Court of Appeals for the Federal Circuit (CAFC) reversed a decision of the U.S. District Court for the Southern District of New York rejecting the district court’s claim construction and holding that Hong Kong uCloudlink Network (uCloudlink) was entitled to summary judgment of non-infringement (SIMO Holdings Inc. v. Hong Kong uCloudlink Network). In particular, the CAFC concluded that the district court erred in not requiring the disputed claim to require two or more non-local calls databases and held that SIMO did not identify a triable issue on the question of whether the accused products lack a non-local calls database.

In contrast to his one time colleague, former Federal Circuit Chief Judge Randall Rader earlier this month filed a Declaration supporting Samsung Electronics in its Opposition to Ericsson, Inc.’s Application for Anti-Interference Injunction relating to Samsung’s lawsuit in the Wuhan Intermediate People’s Court of China. Retired Federal Circuit Judge Paul Michel recently filed an amicus brief supporting Ericsson in the case and calling into question the procedures of the Wuhan court.

On January 5, the Honorable Paul R. Michel filed an amicus brief in support of Ericsson’s Emergency Application for an Anti-Interference Injunction related to Samsung’s lawsuit filed in the Wuhan Intermediate People’s Court of China (the Wuhan Action). In response to Ericsson’s motion filed on December 28, 2020, the United States Federal District Court for the Eastern District of Texas issued a temporary restraining order against Samsung in the FRAND (fair, reasonable and non-discriminatory licensing rates) lawsuit. Michel’s brief addressed the “substantial notice and due process concerns associated with [an] anti-suit injunction issued by the Wuhan Court.”

Eleven amicus briefs were docketed during the last two business days of 2020 in United States v. Arthrex, Inc., et al., which is scheduled for oral argument on March 1, 2021. Several of the briefs were filed by independent inventors, who implored the Court to acknowledge the stories of entrepreneurs and small inventors who have been adversely impacted by the Patent Trial and Appeal Board (PTAB), in part because Administrative Patent Judges (APJs) are presently unaccountable.

On December 29, the United States Court of Appeals for the Federal Circuit (CAFC) affirmed a district court’s decision dismissing Simio’s patent infringement action against FlexSim Software Products (FlexSim) and finding Simio’s claims patent ineligible under 35 U.S.C. § 101 (Simio v. FlexSim Software Products, Inc.). The CAFC also affirmed the district court’s dismissal of Simio’s motion for leave to file an amended complaint on the grounds of futility and, alternatively, on the ground that Simio failed to show good cause for its untimely motion for leave to amend.

In Part I of this five-part series, the authors reviewed the law behind subsequent patent applications. In Part II, we reviewed the different types of subsequent applications. In Parts III and IV we discussed various implications of the types of subsequent applicants. And now, in Part V, we provide practice tips drawn from the case law cited in this series, as well as derived from omphaloskepsis.

American Axle & Manufacturing, Inc. filed a petition for certiorari with the U.S. Supreme Court on December 28, 2020, asking it to review the Federal Circuit’s July 31, 2020 modified judgment and October 2019 panel opinion in a closely-watched Section 101 patent eligibility case involving driveshaft automotive technology. The Federal Circuit has been sharply divided by the issues presented, leading Judge Moore to refer to the original panel’s analysis as “validity goulash” and to state that the “majority’s Nothing More test, like the great American work The Raven from which it is surely borrowing, will, as in the poem, lead to insanity.”

In 2015, Randy dela Fuente launched Snapizzi. Randy had bet big, putting his career, savings, and company at risk. Later, Randy brought in a business partner, Chris Scoones, who cleaned out his savings and mortgaged his house. But they believed in the patent. On the patent’s government-issued cover, it stated that Snapizzi would have the “right to exclude others from making, using, offering for sale, or selling” the invention. This meant that U.S. Patent No. 8,794,506 would protect their company from infringers and give them enough time to carve a toehold in the market. That patent cover also said that the patent was “granted under law”, which meant that it was a legally granted and presumed valid property right. In America, we are a nation of laws. Randy trusted the U.S. government, and this made the burden of huge risk much more tolerable. But in December 2019, a court held that the claims are all ineligible for patenting because they are “abstract ideas”.

On December 23, the United States Court of Appeals for the Federal Circuit (CAFC) vacated a decision of the USPTO’s Patent Trial and Appeals Board (PTAB), holding that the PTAB’s conclusion that Raytheon Technology Corp.’s (Raytheon’s) patent was non-obvious lacked substantial evidence. See General Electric Company v. Raytheon Technologies Corporation. The CAFC also found that General Electric Company (GE) had alleged sufficient facts to establish that it was engaging in activity that created a substantial risk of future infringement, and therefore had standing to bring the appeal.

While coronavirus spent the majority of 2020 wreaking havoc on earth, pharmaceutical companies have been busy at work trying to invent a vaccine to combat it. Several companies, such as Pfizer, Moderna and AstraZeneca, have competed neck and neck to be the first to deliver a cure to the world. Renowned pharmaceutical companies have been successful in developing the vaccine, which will be protected under the Trade-Related Aspects of Intellectual Property Rights Agreement (TRIPS).

As the world bids good riddance to 2020, cursed as it has been by the COVID-19 pandemic and its attendant shutdown of major swathes of the globe’s economy, this list of the Top 10 Patents of 2020 hopefully serves as a reminder that—although the world has missed out on concerts and sporting events aplenty—this year has not been a wasted opportunity for inventors. The world of patent law may be steeped in the tradition of legal precedent but the technologies covered by patents themselves are forward-looking, promising days of driverless vehicle commutes, personalized cancer treatments and fewer awkward moments on Zoom calls. This list does not purport to be an authoritative collection of the most economically valuable technologies protected by patents during 2020, but it offers an honest assessment of technologies that may provide an array of social benefits to consumers long after we ring out the current year.

Chief Judge McMahon, in deciding the defendant’s motion to compel arbitration, ruled the arbitration clause did not prevent Jedi from accessing the federal district court and refused to compel arbitration. “The fact that Mr. Haan signed up for SCRUFF is insufficient to conclude that his actions bound Jedi to Perry’s TOS,” McMahon wrote. “For there to be an agreement to arbitrate, there must be evidence that Jedi (not Haan) knowingly agreed to Perry’s TOS and the arbitration clause contained within it. Since Jedi never signed up for SCRUF, there must be evidence that Jedi authorized Haan to assent to the clause on its behalf.”

Novel and non-obvious can be easily used to describe the events of 2020, both here in the United States and around the world. Despite all the challenges, there have been positive developments in the way we conduct business—and that certainly was true at the U.S. Patent and Trademark Office (USPTO). Below we recap some of the most significant developments at the USPTO in 2020 and topics to keep an eye on in 2021.